FindTrial
Sign In

Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Phase I/II study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220022
Enrollment
Unknown
Registered
2005-09-01
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PS=0-2, Age < 75 yrs, with target leasion according to RECEST

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Initial safety, PK parameter of bevacizumab—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026